Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

WHO SAGE says Oxford's coronavirus vaccine is safe and likely to be efficacious in older adults, and recommends its use in this age group.

© John Cairns

Our vaccine work is progressing quickly. To ensure you have the latest information or to find out more about the trial, please visit the Oxford COVID-19 vaccine web hub or visit the COVID-19 trial website.

The World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) yesterday produced guidelines for the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine developed by the University of Oxford with its partner AstraZeneca.

The WHO has recommended that two standard doses of ChAdOx1 nCoV-19 be administered at an 8- to 12-week interval in people aged 18 years and older. This dosing regimen was shown in clinical trials to be safe and effective in preventing symptomatic COVID-19, with no severe cases and no hospitalisations from COVID-19 more than 14 days after the second dose.

The new guidance marks a key step towards the University and AstraZeneca’s goal of providing global access to the vaccine, which is being made available on a not-for-profit basis during the pandemic. The vaccine is easily manufactured, transported and stored at domestic fridge temperature (2-8 degrees C), so can be easily administered in existing healthcare settings, allowing for the vaccine to be deployed rapidly around the world.

Andrew Pollard, Professor of Paediatric Infection and Immunity, and Chief Investigator on the Oxford vaccine trial, said: ‘The new guidance from WHO is an important milestone in extending access to the Oxford-AZ vaccine to all corners of the world and providing further endorsement that after rigorous scrutiny by the WHO Strategic Advisory Group of Experts the vaccine can be used to help protect populations from the coronavirus pandemic.’

Sarah Gilbert, Professor of Vaccinology, and Chief Investigator on the Oxford vaccine trial, said: ‘It is excellent news that the WHO has recommended use of the SARS CoV-2 vaccine first produced in Oxford. This decision paves the way to more widespread use of the vaccine to protect people against COVID-19 and gain control of the pandemic.’

Similar stories

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

COVID-19 vaccine messaging that focuses on personal benefits is most effective with those who are hesitant

For the one in ten who say they won’t take a COVID-19 vaccine, messaging that focuses on personal rather than collective benefits is more effective.

Preliminary data suggests mixing Covid-19 vaccine increases reactogenicity

Research, from Com-COV study comparing mixed dosing schedules of Pfizer / Oxford-AstraZeneca vaccines, shows increase in the frequency of mild-moderate symptoms in those receiving either mixed dosing schedule. Adverse reactions were short-lived, with no other safety concerns. Impact of mixed schedules on immunogenicity unknown as yet, with data to follow from this study.

Oxford vaccine professor: rich countries have a moral duty to share their COVID-19 shots

Andrew Pollard writes about vaccine equity in his article for The Conversation.

Increasing vaccine uptake among ethnic minorities

Dr Samantha Vanderslott and Dr Seilesh Kadambari discuss their collaborative approach to providing ethnic minority groups with information on vaccines.

COVID-19 elimination, not mitigation, best for health, economy and civil liberties – Oxford study

Countries which aimed to eliminate COVID-19 registered fewer deaths, better economic performance, and fewer restrictions and lockdowns, according to an article in The Lancet.